RadNet Reports Fourth Quarter and Full Year 2013 Results, Releases 2014 Financial Guidance and Announces a Proposed Refinancing Transaction of its $200 million 10 3/8% Senior Unsecured Notes For the

RadNet Reports Fourth Quarter and Full

Year 2013 Results, Releases 2014 Financial Guidance and Announces a Proposed Refinancing Transaction of its $200 million 10 3/8%

Senior Unsecured Notes

LOS ANGELES, California, March

3, 2014 - RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient

diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, today reported financial

results for its fourth quarter and full year ended December 31, 2013.

Fourth Quarter Report:

For the fourth quarter of 2013, RadNet reported

Revenue, Adjusted EBITDA(1) and Net Income of $178.3 million, $31.9 million and $1.2 million, respectively. Revenue

increased $19.0 million (or 11.9%), Adjusted EBITDA(1) increased $7.3 million (or 30.0%) and Net Income increased

$5.2 million over the fourth quarter of 2012 (excluding the $55.9 million non-cash income tax benefit recognized in the fourth

Net Income for the fourth quarter was $0.03

per diluted share, compared to a Net Loss of $(0.10) per share in the fourth quarter of 2012 (again adjusting for the $55.9 million

non-cash income tax benefit recognized in the fourth quarter of 2012). These per share values are based upon a weighted average

number of diluted shares outstanding of 39.6 million in the fourth quarter of 2013 and 38.3 million of basic shares outstanding

in the fourth quarter of 2012.

Affecting Net Income in the fourth quarter

of 2013 were certain non-cash expenses and non-recurring items including: $529,000 of non-cash employee stock compensation expense

resulting from the vesting of certain options, warrants and restricted stock; $494,000 of severance paid in connection with headcount

reductions related to cost savings initiatives; $675,000 loss on the disposal of certain capital equipment; and $1.2 million of

amortization of deferred financing fees and discount on issuance of debt related to our existing credit facilities and 10 3/8%

senior unsecured notes.

For the fourth quarter of 2013, as compared

with the prior year's fourth quarter, MRI volume increased 16.8%, CT volume increased 5.0% and PET/CT volume decreased 4.7%.

Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased

12.2% over the prior year's fourth quarter. On a same-center basis, including only those centers which were part of RadNet

for both the fourth quarters of 2013 and 2012, MRI volume increased 5.5%, CT volume decreased 1.7% and PET/CT volume decreased

1.0%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other

exams, increased 2.4% over the prior year's same quarter.

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented "We are very pleased with our fourth quarter performance. As compared with the prior year's

fourth quarter performance, we had significant increases in aggregate Revenue and Adjusted EBITDA(1) and same center

revenue and procedural volumes. Although on a comparison basis we were benefited by the impact of Hurricane Sandy in 2012's

fourth quarter, we experienced increasing volumes in the fourth quarter as compared to the prior quarters in 2013. While we cannot

determine with certainty why volumes improved, we believe we may have benefited from the impact of increased procedures from patients

in large-deductible health plans who sought to utilize medical services prior to these deductibles resetting in 2014. Also, we

noted additional patient volume in our centers from those who were early enrollees in health exchanges under the Healthcare Reform

Act. The strength of our 2013 fourth quarter provides us confidence about our business as we enter 2014."

For full year 2013, the Company reported Revenue,

Adjusted EBITDA(1) and Net Income of $703.0 million, $112.8 million and $2.1 million, respectively. Revenue increased

$55.8 million (or 8.6%), Adjusted EBITDA(1) decreased $759,000 (or 0.7%) and Net Income decreased $2.5 million (excluding

the $55.2 million non-cash income tax benefit recognized during 2012), respectively, from full year 2012 results. Net Income for

2013 was $0.05 per diluted share, compared to Net Income of $0.12 per diluted share in 2012 (based upon a weighted average number

of diluted shares outstanding of 39.8 million and 39.2 million in 2013 and 2012, respectively and after excluding the $55.2 million

non-cash income tax benefit recognized during 2012).

Affecting Net Income in 2013 were certain

non-cash expenses and non-recurring items including: $2.6 million of non-cash employee stock compensation expense resulting from

the vesting of certain options, warrants and restricted stock; $806,000 of severance paid in connection with headcount reductions

related to cost savings initiatives; $1.0 million loss on the disposal of certain capital equipment; $2.1 million gain on the

sale of imaging centers; and $4.6 million of amortization of deferred financing fees and discount on issuance of debt related

to our existing credit facilities and 10 3/8% senior unsecured notes.

For the year ended December 31, 2013, as compared

to 2012, MRI volume increased 12.2%, CT volume increased 1.2% and PET/CT volume decreased 2.4%. Overall volume, taking into account

routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 9.3% for the twelve months of 2013

Actual 2013 Results vs. 2013 Revised Guidance:

The following compares the Company's

actual 2013 performance with previously announced revised guidance levels.

Dr. Berger commented, "Our fourth quarter

performance was stronger than that which was projected when we issued our revised full year 2013 guidance levels. As a result,

we exceeded the high-end of our Revenue and EBITDA guidance levels. With respect to Free Cash Flow generation, I am also pleased

that our actual results were at the top of our guidance range."

2014 Fiscal Year Guidance

For its 2014 fiscal year, RadNet announces

its guidance ranges as follows:

"As reflected in our 2014

guidance, we are optimistic about 2014. In December of last year, we announced a $20 million-$22 million negative impact to our

2014 revenue from the changes in the Medicare Physician Fee Schedule. In response to this, we launched a plan to eliminate $30

million of costs from our business. Our 2014 guidance reflects our confidence in achieving at least $20 million of these costs

savings in 2014," added Dr. Berger.

Dr. Berger continued, "Our guidance also

incorporates what we are projecting to be a soft first quarter in 2014 due to the unusually severe winter weather conditions that

have existed in the northeastern part of the United States in January and February of this year."

Proposed Refinancing Transaction

The Company currently intends to pursue a refinancing

of its 10 3/8% Senior Unsecured Notes due 2018. The proposed refinancing may include a tender offer for, or redemption of, the

Company's senior unsecured notes, which would be replaced by new senior secured second lien term loan debt and additional

indebtedness under the Company's senior secured first lien credit facility.

The potential refinancing transaction would

be subject to negotiations with current lenders for the Company's senior secured debt and market and other conditions. As

such, there can be no assurance that the Company will complete a refinancing transaction on terms that are favorable to the Company

or its investors. The Company may engage from time to time in discussions with creditors of the Company and holders of the senior

unsecured notes, as well as their respective advisors, as the Company pursues such potential refinancing transaction.

Mark Stolper, Executive Vice President and

Chief Financial Officer of RadNet, commented "We have publicly discussed in recent quarters the possibility of lowering our

cost of capital through refinancing our 10 3/8% Senior Unsecured Notes with less expensive capital. After having consulted with

our investment banking advisors, we expect to launch a refinancing transaction designed to replace our Senior Unsecured Notes with

a Second Lien Term Loan and additional borrowings under our existing credit facility, subject to market and other conditions. Our

objective is to lower our cash interest obligations, provide us with additional operating flexibility and lengthen the maturity

of our most junior debt capital. If successful, we currently expect to consummate a transaction in April."

Conference Call for Today

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, at 10:30 a.m.

Eastern Standard Time. During the call, management will discuss the Company's 2013 fourth quarter and year-end results.

Conference Call Details:

Date: Monday, March 3, 2014